J102-0282 Screening compound: 2-{3-oxo-2H,3H,5H,6H,7H,8H,9H-cyclohepta[c]pyridazin-2-yl}-N-{[1-({[1,2,4]triazolo[4,3-a]pyridin-3-yl}methyl)cyclohexyl]methyl}acetamide

J102-0282 Screening compound: 2-{3-oxo-2H,3H,5H,6H,7H,8H,9H-cyclohepta[c]pyridazin-2-yl}-N-{[1-({[1,2,4]triazolo[4,3-a]pyridin-3-yl}methyl)cyclohexyl]methyl}acetamide
J102-0282 Screening compound: 2-{3-oxo-2H,3H,5H,6H,7H,8H,9H-cyclohepta[c]pyridazin-2-yl}-N-{[1-({[1,2,4]triazolo[4,3-a]pyridin-3-yl}methyl)cyclohexyl]methyl}acetamide alternative view

Chemical Structure Depiction of ChemDiv screening compound J102-0282
2-{3-oxo-2H,3H,5H,6H,7H,8H,9H-cyclohepta[c]pyridazin-2-yl}-N-{[1-({[1,2,4]triazolo[4,3-a]pyridin-3-yl}methyl)cyclohexyl]methyl}acetamide

Available from 1 mg

Formats:

  • Glass Vials (4ml Glass Vials VWR #97047-678)
  • 96-tube racks (Matrix #4247 96-well 1.4ml sealed with capmats, empty cols 1 & 12, 100uL of 10mM)

Shiptime: 1 week worldwide delivery in most cases

Compound Identifiers

ChemDiv Compound ID

J102-0282

Molecular Formula

C25H32N6O2 (C25 H32 N6 O2)

Compound Name

2-{3-oxo-2H,3H,5H,6H,7H,8H,9H-cyclohepta[c]pyridazin-2-yl}-N-{[1-({[1,2,4]triazolo[4,3-a]pyridin-3-yl}methyl)cyclohexyl]methyl}acetamide

IUPAC name

2-{3-oxo-2H3H5H6H7H8H9H-cyclohepta[c]pyridazin-2-yl}-N-{[1-({[124]triazolo[43-a]pyridin-3-yl}methyl)cyclohexyl]methyl}acetamide

SMILES

O=C(CN1N=C(CCCCC2)C2=CC1=O)NCC1(Cc2nnc3n2cccc3)CCCCC1

InChI

InChI=1S/C25H32N6O2/c32-23(17-31-24(33)15-19-9-3-1-4-10-20(19)29-31)26-18-25(12-6-2-7-13-25)16-22-28-27-21-11-5-8-14-30(21)22/h5,8,11,14-15H,1-4,6-7,9-10,12-13,16-18H2,(H,26,32)

InChI Key

LCHKQWGCCSWQCJ-UHFFFAOYSA-N

MDL Number (MFCD)

MFCD27963058

Chemical and Physical Properties

Saltdata

n/a

Molecular Weight

448.57

Hydrogen Bond Acceptors Count

7.00

Hydrogen Bond Donors Count

1.00

Rotatable Bond Count

7.00

Number of Nitrogen and Oxygen Atoms

8

Partition Coefficient, logP

2.003

Distribution Coefficient, logD

2.003

Water Solubility, LogSw

-2.40

Polar Surface Area

75.542

Acid Dissociation Constant (pKa)

14.95

Base Dissociation Constant (pKb)

-0.44

Number of Chiral Centers

0.00

Percent sp3 carbon bonding

56.00

J102-0282 in Drug Discovery

Included in Screening Libraries

300k Representative Compounds Library (Bemis-Murcko Clustering Algorithm) (286253 compounds)

GABA Library (7115 compounds)

GPCR Targeted Library (31838 compounds)

Protein-Protein Interaction Library (218420 compounds)

Beyond the Flatland Library sp3 enriched (92988 compounds)

Included in 1.7M Stock Database

Therapeutical areas:
  • Eye
  • Musculoskeletal
  • Respiratory tract
  • Nervous system
  • Congenital
  • Skin
  • Metabolic
  • Endocrine
Targets:
  • GPCR
  • Ion Channels
  • GPCR
Mechanism of action:
  • Receptor's ligands
  • Receptor's ligands
  • PPI modulators
Structure:
  • Cyclic compounds

References: we are preparing a list of scientific research reports with J102-0282 chemical compound. It will be published here after verification.

Frequently Asked Questions

How to purchase chemical compound J102-0282?
Check Price and Availability of J102-0282, then you can add required amount to the Shopping Cart. In the Shopping Cart you can again refine your selection. Once you are sure that it’s exactly what you want you can move forward with the Checkout (to pay online by credit card, or via PayPal), or Request a Quote.
What is the minimum amount of J102-0282 you sell to drug discovery company or institution?
Available from 1 mg in Glass Vials or 96-tube racks.
Delivery options for J102-0282
ChemDiv sends parcels with Express services (UPS, WC).
  • 1–2 days for small orders
  • 2–4 weeks for large selections
Delivery formats for J102-0282
  • 0.5–50 mg of dry powder sample in single glass vials, custom vials
  • DMSO solutions frozen 10μl–250μl@10mM (96 and 384 format)

Custom synthesis of J102-0282 available by request